| Trial ID: | L3373 |
| Source ID: | NCT00145925
|
| Associated Drug: |
Perindopril-Indapamide
|
| Title: |
Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Perindopril-indapamide|DRUG: Gliclazide MR-based glucose lowering
|
| Outcome Measures: |
Primary: Composite of non-fatal stroke, non-fatal myocardial infarction or death from any cardiovascular cause, July 2001 - December 2007|Composite of new or substantially worsening nephropathy or microvascular eye disease., July 2001 - December 2007 | Secondary: Includes cerebrovascular disease, coronary heart disease, heart failure, peripheral vascular disease, cardiovascular and all-cause mortality, microalbuminuria, visual deterioration, new or worsening nephropathy, cognitive function, and dementia., July 2001 - December 2007
|
| Sponsor/Collaborators: |
Sponsor: The George Institute | Collaborators: Institut de Recherches Internationales Servier|University of Sydney|National Health and Medical Research Council, Australia
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
11140
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE|Primary Purpose: PREVENTION
|
| Start Date: |
2001-06
|
| Completion Date: |
2008-03
|
| Results First Posted: |
|
| Last Update Posted: |
2025-04-11
|
| Locations: |
The University of Melbourne, Melbourne, Victoria, 3010, Australia|University of Montreal, Montreal, Quebec, H26 1X2, Canada|Cardiovascular Institute & Fu Wai Hospital, Beijing, Beijing, 100037, China|The Julius Center for Health Sciences and Primary Care, Utrecht, 3508 BA, Netherlands|Imperial College School of Medicine, London, W2 1PG, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT00145925
|
